Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's EBIT?
- CytomX Therapeutics (CTMX) reported EBIT of -$23.78M in Q2 2026.
- How has CytomX Therapeutics's EBIT changed year-over-year?
- CytomX Therapeutics's EBIT decreased by 1749.2% year-over-year, from -$1.29M to -$23.78M.
- What is the long-term trend for CytomX Therapeutics's EBIT?
- Over 4 years (2021 to 2025), CytomX Therapeutics's EBIT has grown at a -33.7% compound annual growth rate (CAGR), from -$116.04M to -$22.37M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about CytomX Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude